| Lindsay Anne Rhodes, MD | |
|
53 Sewall St, Portland, ME 04102-2625 | |
| (207) 828-2020 | |
| Not Available |
| Full Name | Lindsay Anne Rhodes |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 16 Years |
| Location | 53 Sewall St, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396999587 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eyecare Medical Group | 7517995129 | 13 |
News Archive
Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.
Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Genome wide association studies (GWAS) scan the entire genome in order to pinpoint genetic variants associated with a particular disease. The technique is employed to identify biological pathways - the series of actions and changes that have occurred in cells and genetic material - that can be linked to the causation of a disease.
› Verified 1 days ago
| Entity Name | Eyecare Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467557280 PECOS PAC ID: 7517995129 Enrollment ID: O20050803000582 |
News Archive
Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.
Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Genome wide association studies (GWAS) scan the entire genome in order to pinpoint genetic variants associated with a particular disease. The technique is employed to identify biological pathways - the series of actions and changes that have occurred in cells and genetic material - that can be linked to the causation of a disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsay Anne Rhodes, MD 53 Sewall St, Portland, ME 04102-2625 Ph: (207) 828-2020 | Lindsay Anne Rhodes, MD 53 Sewall St, Portland, ME 04102-2625 Ph: (207) 828-2020 |
News Archive
Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.
Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Genome wide association studies (GWAS) scan the entire genome in order to pinpoint genetic variants associated with a particular disease. The technique is employed to identify biological pathways - the series of actions and changes that have occurred in cells and genetic material - that can be linked to the causation of a disease.
› Verified 1 days ago
Scott M Steidl, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 53 Sewall Street, Portland, ME 04102 Phone: 207-828-2020 Fax: 207-773-7034 | |
Linda K Morrison, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 331 Veranda St, Portland, ME 04103 Phone: 207-828-2402 Fax: 207-872-8242 | |
Mr. Sirus Hamzavi, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 15 Lowell St, Portland, ME 04102 Phone: 207-774-8277 Fax: 207-871-1415 | |
Robert S Cady, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 15 Lowell St, Portland, ME 04102 Phone: 207-774-8277 Fax: 207-699-5850 | |
Robert W Daly, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 53 Sewall St, Portland, ME 04102 Phone: 207-828-2020 Fax: 207-773-7034 | |
Nathaniel R Gelinas, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 15 Lowell St, Portland, ME 04102 Phone: 207-774-8277 Fax: 207-523-5310 | |
Curtis Mackay Libby, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 15 Lowell St, Portland, ME 04102 Phone: 207-774-8277 Fax: 207-699-5850 |